{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:54:27Z","timestamp":1792457667861,"version":"4.5.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study aimed at investigating antiepileptic drug (AED) prescription preferences in patients with brain tumor-related epilepsy (BTRE) among the European neuro-oncology community, the considerations that play a role when initiating AED treatment, the organization of care, and practices with regard to AED withdrawal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A digital survey containing 31 questions about prescription preferences of AEDs was set out among members of the European Association of Neuro-Oncology (EANO).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 198 respondents treating patients with BTRE participated of whom 179 completed the entire survey. Levetiracetam was the first choice in patients with BTRE for almost all respondents (90% [162\/181]). Levetiracetam was considered the most effective AED in reducing seizure frequency (72% [131\/181]) and having the least adverse effects (48% [87\/181]). Common alternatives for levetiracetam as equivalent first choice included lacosamide (33% [59\/181]), lamotrigine (22% [40\/181]), and valproic acid (21% [38\/181]). Most crucial factors to choose a specific AED were potential adverse effects (82% [148\/181]) and interactions with antitumor treatments (76% [137\/181]). In the majority of patients, neuro-oncologists were involved in the treatment of seizures (73% [132\/181])). Other relevant findings were that a minority of respondents ever prescribe AEDs in brain tumor patients without epilepsy solely as prophylaxis (29% [53\/181]), but a majority routinely considers complete AED withdrawal in BTRE patients who are seizure-free after antitumor treatment (79% [141\/179]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results show that among European professionals treating patients with BTRE levetiracetam is considered the first choice AED, with the presumed highest efficacy and least adverse effects.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/nop\/npab059","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T17:05:22Z","timestamp":1634835922000},"page":"105-113","source":"Crossref","is-referenced-by-count":27,"title":["Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3700-8906","authenticated-orcid":false,"given":"Pim B","family":"van der Meer","sequence":"first","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-9895","authenticated-orcid":false,"given":"Linda","family":"Dirven","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden , the Netherlands"},{"name":"Department of Neurology, Haaglanden Medical Center , The Hague , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5710-5127","authenticated-orcid":false,"given":"Martin J","family":"van den Bent","sequence":"additional","affiliation":[{"name":"Brain Tumor Center at Erasmus Medical Center Cancer Institute , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-2315","authenticated-orcid":false,"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J B","family":"Taphoorn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden , the Netherlands"},{"name":"Department of Neurology, Haaglanden Medical Center , The Hague , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Rud\u00e1","sequence":"additional","affiliation":[{"name":"Department of Neurology, Castelfranco Veneto Hospital , Castelfranco Veneto , Italy"},{"name":"Department of Neuro-Oncology, City of Health and Science and University of Turin , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan A F","family":"Koekkoek","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden , the Netherlands"},{"name":"Department of Neurology, Haaglanden Medical Center , The Hague , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"2022101914171291700_CIT0001","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/B978-0-12-802997-8.00016-5","article-title":"Epilepsy and brain tumors","volume":"134","author":"Englot","year":"2016","journal-title":"Handb Clin Neurol."},{"issue":"9","key":"2022101914171291700_CIT0002","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S1470-2045(14)70011-7","article-title":"EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma","volume":"15","author":"Weller","year":"2014","journal-title":"Lancet Oncol."},{"key":"2022101914171291700_CIT0003","doi-asserted-by":"crossref","first-page":"iv55","DOI":"10.1093\/neuonc\/nos199","article-title":"Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments","volume":"14","author":"Rud\u00e0","year":"2012","journal-title":"Neuro Oncol"},{"issue":"4","key":"2022101914171291700_CIT0004","first-page":"245","article-title":"Seizures and cancer: drug interactions of anticonvulsants with chemotherapeutic agents, tyrosine kinase inhibitors and glucocorticoids","volume":"3","author":"B\u00e9nit","year":"2016","journal-title":"Neurooncol Pract."},{"issue":"5","key":"2022101914171291700_CIT0005","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","article-title":"Combining antiepileptic drugs \u2013 rational polytherapy?","volume":"20","author":"Brodie","year":"2011","journal-title":"Seizure."},{"issue":"6","key":"2022101914171291700_CIT0006","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3171\/2016.4.JNS16245","article-title":"Prophylactic antiepileptic drug administration following brain tumor resection: results of a recent AANS\/CNS Section on Tumors survey","volume":"126","author":"Dewan","year":"2017","journal-title":"J Neurosurg."},{"key":"2022101914171291700_CIT0007","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1093\/neuonc\/nox238.045","article-title":"Prophylactic antiepileptic drugs in meningioma surgery \u2013 survey of clinical practice in the UK","volume":"20","author":"Giraldi","year":"2018","journal-title":"Neuro Oncol"},{"issue":"1","key":"2022101914171291700_CIT0008","first-page":"17","article-title":"Antiepileptic drug usage in neuro-oncology: a practice survey","volume":"2","author":"Parhi","year":"2019","journal-title":"Int J Neurooncol."},{"issue":"2","key":"2022101914171291700_CIT0009","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-004-6912-4","article-title":"Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors","volume":"74","author":"Siomin","year":"2005","journal-title":"J Neurooncol."},{"issue":"1","key":"2022101914171291700_CIT0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4236\/nm.2015.61003","article-title":"Brain tumours and prophylactic antiepileptic drug prescribing patterns by neurosurgeons practising in Australasia","volume":"6","author":"Tsimiklis","year":"2015","journal-title":"Neurosci Med"},{"issue":"1","key":"2022101914171291700_CIT0011","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1472-6963-3-23","article-title":"Can surveying practitioners about their practices help identify priority clinical practice guideline topics?","volume":"3","author":"Brouwers","year":"2003","journal-title":"BMC Health Serv Res."},{"issue":"1","key":"2022101914171291700_CIT0012","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11060-021-03800-z","article-title":"The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide","volume":"154","author":"van Opijnen","year":"2021","journal-title":"J Neurooncol."},{"issue":"5","key":"2022101914171291700_CIT0013","first-page":"501","article-title":"Efficacy of antiepileptic drugs in glioma patients with epilepsy: a systematic review","volume":"8","author":"de Bruin","year":"2021","journal-title":"Neurooncol Pract."},{"issue":"2","key":"2022101914171291700_CIT0014","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2020.11.003","article-title":"Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up","volume":"32","author":"Roth","year":"2021","journal-title":"Ann Oncol."},{"issue":"5","key":"2022101914171291700_CIT0015","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/epi.16880","article-title":"First-line antiepileptic drug treatment in glioma patients with epilepsy: levetiracetam vs valproic acid","volume":"62","author":"van der Meer","year":"2021","journal-title":"Epilepsia."},{"issue":"5","key":"2022101914171291700_CIT0016","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jamaneurol.2020.0032","article-title":"Tolerability of antiseizure medications in individuals with newly diagnosed epilepsy","volume":"77","author":"Alsfouk","year":"2020","journal-title":"JAMA Neurol."},{"issue":"1","key":"2022101914171291700_CIT0017","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11060-017-2628-0","article-title":"Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study","volume":"136","author":"Rud\u00e0","year":"2018","journal-title":"J Neurooncol."},{"issue":"4","key":"2022101914171291700_CIT0018","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/epi.16486","article-title":"Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: results from a prospective, noninterventional study in European clinical practice (VIBES)","volume":"61","author":"Rud\u00e0","year":"2020","journal-title":"Epilepsia."},{"issue":"1","key":"2022101914171291700_CIT0019","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/ane.12809","article-title":"Outcome of cancer-related seizures in patients treated with lacosamide","volume":"137","author":"Toledo","year":"2018","journal-title":"Acta Neurol Scand."},{"key":"2022101914171291700_CIT0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yebeh.2016.09.033","article-title":"NEOPLASM study: real-life use of lacosamide in patients with brain tumor-related epilepsy","volume":"65","author":"Villanueva","year":"2016","journal-title":"Epilepsy Behav."},{"issue":"6","key":"2022101914171291700_CIT0021","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3171\/2013.1.JNS12397","article-title":"Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article","volume":"118","author":"Saria","year":"2013","journal-title":"J Neurosurg."},{"issue":"11","key":"2022101914171291700_CIT0022","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1007\/s00415-011-6132-8","article-title":"Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability","volume":"258","author":"Maschio","year":"2011","journal-title":"J Neurol."},{"key":"2022101914171291700_CIT0023","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.yebeh.2017.05.031","article-title":"Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: a prospective explorative study with a historical control group","volume":"73","author":"Maschio","year":"2017","journal-title":"Epilepsy Behav."},{"issue":"5","key":"2022101914171291700_CIT0024","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1212\/01.WNL.0000079374.78589.1B","article-title":"Temporal lobe tumoral epilepsy: characteristics and predictors of surgical outcome","volume":"61","author":"Zaatreh","year":"2003","journal-title":"Neurology."},{"issue":"7","key":"2022101914171291700_CIT0025","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1528-1157.2002.39501.x","article-title":"Frontal lobe tumoral epilepsy: clinical, neurophysiologic features and predictors of surgical outcome","volume":"43","author":"Zaatreh","year":"2002","journal-title":"Epilepsia."},{"issue":"4","key":"2022101914171291700_CIT0026","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3171\/2017.10.JNS172236","article-title":"Effectiveness of perioperative antiepileptic drug prophylaxis for early and late seizures following oncologic neurosurgery: a meta-analysis","volume":"130","author":"Joiner","year":"2019","journal-title":"J Neurosurg"},{"issue":"3","key":"2022101914171291700_CIT0027","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"issue":"4","key":"2022101914171291700_CIT0028","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/neuonc\/noz034","article-title":"Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines","volume":"21","author":"Chang","year":"2019","journal-title":"Neuro Oncol."},{"issue":"10","key":"2022101914171291700_CIT0029","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1212\/WNL.54.10.1886","article-title":"Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"54","author":"Glantz","year":"2000","journal-title":"Neurology."},{"issue":"6","key":"2022101914171291700_CIT0030","first-page":"583","article-title":"Neuro-Oncology Practice Clinical Debate: long-term antiepileptic drug prophylaxis in patients with glioma","volume":"7","author":"Stocksdale","year":"2020","journal-title":"Neurooncol Pract."},{"key":"2022101914171291700_CIT0031","article-title":"Antiepileptic drugs for preventing seizures in people with brain tumors","volume":"2","author":"Tremont-Lukats","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2022101914171291700_CIT0032","article-title":"Antiepileptic drugs as prophylaxis for post-craniotomy seizures","volume":"3","author":"Weston","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2022101914171291700_CIT0033","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1136\/jnnp-2019-ABN.25","article-title":"TM1-1 Seizure prophylaxis in gliomas (SPRING): a phase III randomised controlled trial comparing prophylactic levetiracetam versus no prophylactic anti-epileptic drug in glioma surgery","volume":"90","author":"Jenkinson","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"2022101914171291700_CIT0034","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11060-019-03117-y","article-title":"Withdrawal of antiepileptic drugs in patients with low grade and anaplastic glioma after long-term seizure freedom: a prospective observational study","volume":"142","author":"Kerkhof","year":"2019","journal-title":"J Neurooncol."},{"issue":"3","key":"2022101914171291700_CIT0035","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11060-011-0779-y","article-title":"Outcomes after discontinuation of antiepileptic drugs after surgery in patients with low grade brain tumors and meningiomas","volume":"107","author":"Das","year":"2012","journal-title":"J Neurooncol."},{"issue":"2","key":"2022101914171291700_CIT0036","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1528-1167.2006.00431.x","article-title":"Seizure recurrence and risk factors after antiepilepsy drug withdrawal in children with brain tumors","volume":"47","author":"Khan","year":"2006","journal-title":"Epilepsia."},{"issue":"10","key":"2022101914171291700_CIT0037","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","article-title":"Shared decision making: a model for clinical practice","volume":"27","author":"Elwyn","year":"2012","journal-title":"J Gen Intern Med."},{"issue":"2","key":"2022101914171291700_CIT0038","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/14737175.2016.1219250","article-title":"The withdrawal of antiepileptic drugs in patients with low-grade and anaplastic glioma","volume":"17","author":"Koekkoek","year":"2017","journal-title":"Expert Rev Neurother."}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npab059\/41147382\/npab059.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/9\/2\/105\/46572530\/npab059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/9\/2\/105\/46572530\/npab059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T14:48:22Z","timestamp":1666190902000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/9\/2\/105\/6407589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,10,21]]},"published-print":{"date-parts":[[2022,3,30]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npab059","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2021,10,21]]}}}